Table 3.
Experiences with COVID-19 vaccination.
| Manufacturer - no. (%) | ||
| Pfizer-BioNTech | 120 (57.7%) | |
| Received both doses | 113 (95.0%) | |
| Days between doses - mean (SD) | 21.5 (3.7) | |
| Moderna | 72 (34.6%) | |
| Received both doses | 65 (90.3%) | |
| Days between doses - mean (SD) | 29.5 (3.7) | |
| Johnson & Johnson | 9 (4.3%) | |
| Unsure/no response | 7 (3.7%) | |
| Held/delayed DMT dose for the vaccine - no. (%) a | 24 (15.0%) | |
| Interferons | 10 (41.7%) | |
| Ocrelizumab | 10 (41.7%) | |
| Natalizumab | 4 (16.7%) | |
| After first dose b | After second dose | |
| MS symptom worsening after vaccination - no. (%) | 15 (7.6%) | 26 (14.7%) |
| No vaccine side effects - no. (%) | 48 (23.9%) | 31 (17.3%) |
| Vaccine side effects - no. (%) | 153 (76.1%) | 148 (82.7%) |
| Pain in the arm at injection site | 144 (71.6%) | 119 (66.5%) |
| Swelling in the arm at injection site | 19 (9.5%) | 20 (11.2%) |
| Fever | 9 (4.5%) | 33 (18.4%) |
| Chills | 11 (5.5%) | 39 (21.8%) |
| Tiredness | 60 (29.9%) | 87 (48.6%) |
| Headache | 38 (18.9%) | 65 (36.3%) |
| Muscle aches | 27 (13.4%) | 57 (31.8%) |
| Lightheadedness | 4 (2.0%) | 17 (9.5%) |
| Rash | 2 (1.0%) | 3 (1.7%) |
| Nausea/vomiting | 3 (1.5%) | 15 (8.4%) |
| Diarrhea | 0 (0%) | 4 (2.2%) |
| Swollen or sore lymph nodes | 3 (1.5%) | 4 (2.2%) |
| Allergic reaction | 0 (0%) | 0 (0%) |
| Other | 6 (3.0%) | 12 (6.7%) |
| Duration of side effects, days - median (IQR) | 2 (1-3) | 2 (1-3) |
| Severity of side effects - no. (%) | ||
| Mild (not interfering with daily activities) | 120 (80.0%) | 78 (55.3%) |
| Moderate (interfering with daily activities) | 28 (18.7%) | 38 (27.0%) |
| Severe (unable to perform usual activities or missed work) | 2 (1.3%) | 25 (17.7%) |
a
Among those currently on a disease-modifying therapy.
b
First dose of mRNA vaccine, or single dose of other vaccines.